Richter Gedeon Nyrt./Ft RICHTER
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Richter Gedeon Nyrt.
- Ticker
- Ft RICHTER
- Sector
- Health
- Primary listing
- BUX
- Employees
- 11,155
- Headquarters
- Budapest, Hungary
- Website
- www.gedeonrichter.com
RICHTER Metrics
BasicAdvanced
Ft 2.389T
11.19
Ft 1,180
0.34
Ft 655
4.96%
Price and volume
Market cap
Ft 2.389T
Beta
0.34
52-week high
Ft 13,570
52-week low
Ft 9,380
Average daily volume
196K
Dividend rate
Ft 655
Financial strength
Current ratio
3.786
Quick ratio
2.514
Long term debt to equity
0.063
Total debt to equity
0.07
Dividend payout ratio (TTM)
41.28%
Interest coverage (TTM)
28.80%
Profitability
EBITDA (TTM)
359,846
Gross margin (TTM)
67.29%
Net profit margin (TTM)
23.34%
Operating margin (TTM)
32.96%
Effective tax rate (TTM)
18.40%
Revenue per employee (TTM)
Ft 82,930,000
Management effectiveness
Return on assets (TTM)
11.58%
Return on equity (TTM)
16.20%
Valuation
Price to earnings (TTM)
11.188
Price to revenue (TTM)
2.611
Price to book
1.76
Price to tangible book (TTM)
2.28
Price to free cash flow (TTM)
10.337
Free cash flow yield (TTM)
9.67%
Free cash flow per share (TTM)
1,277.492
Dividend yield (TTM)
4.96%
Forward dividend yield
4.96%
Growth
Revenue change (TTM)
2.40%
Earnings per share change (TTM)
-2.25%
3-year revenue growth (CAGR)
2.65%
10-year revenue growth (CAGR)
9.64%
3-year earnings per share growth (CAGR)
21.20%
10-year earnings per share growth (CAGR)
17.26%
What the Analysts think about RICHTER
Analyst ratings (Buy, Hold, Sell) for Richter Gedeon Nyrt. stock.
Analyst projections of the future price of Richter Gedeon Nyrt. stock.
Bulls say / Bears say
Pharma revenue grew 8.7% at constant exchange rates in H1, while Clean EBIT rose 21%; Richter upgraded its 2026 Clean EBIT outlook to double-digit growth. Strong Vraylar and Reagila sales and efficiency savings are driving the improvement. (Gedeon Richter)
Women’s Healthcare sales grew 7% at constant exchange rates in H1, with faster growth in Q2 and strength in brands including Ryeqo and Lenzetto. Richter has also begun launching its new menopause treatment Fylrevy in selected European markets, adding a further growth opportunity. (Gedeon Richter)
Biotechnology revenue rose 30% at constant exchange rates in H1, supported by biosimilar sales and new launches. Richter’s agreement with Hetero to develop and commercialise generic semaglutide adds longer-term potential, with EU and US filings planned for 2027. (Gedeon Richter, Hetero)
Currency movements are eroding reported results: H1 pharma revenue fell 0.5% despite underlying growth of 8.7%, and HUF 27.1bn in FX losses helped drive net profit down 14%. (Gedeon Richter)
Growth remains uneven: GenMed revenue fell 5% at constant exchange rates in H1 and pharma gross margin declined by 1.2 percentage points. Weaker Eastern European sales and slower traditional contraceptive sales also weigh on Women’s Healthcare. (Gedeon Richter)
Richter’s planned Usymro biosimilar launch has been put on hold after manufacturing compliance issues at partner Bio-Thera, and Richter impaired the product rights to zero. The setback highlights the risk of relying on partners to manufacture key products. (Citeline)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
RICHTER Financial Performance
Revenues and expenses
RICHTER Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing RICHTER
Fund name | Fund size | Ft RICHTER weighting |
|---|---|---|
iShares Edge MSCI EM Value Factor$EMVL | $1.7B | 0.45% |
HSBC MSCI Emerging Markets Islamic Screened Capped$HIEM | $182M | 0.12% |
HSBC MSCI Emerging Markets Islamic Screened Capped£HIES | $182M | 0.12% |
iShares MSCI EM Islamic$ISDE | $835M | 0.12% |
iShares Edge MSCI Emerging Markets Minimum Volatility$EMMV | $503M | 0.07% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by Budapest Stock Exchange.